Immunoassay Interference Blocker Market Size & Share 2024 - 2032

Immunoassay Interference Blocker Market Size

Immunoassay Interference Blocker Market size was valued at USD 289.2 million in 2023, growing at a CAGR of 6.3% between 2024 and 2032, driven by factors such as the growing prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders that necessitates accurate and reliable diagnostic methods. Immunoassays are commonly used for biomarker detection in these conditions, making interference blockers essential for improving diagnostic accuracy.

Moreover, continuous advancements in immunoassay technologies and materials lead to the development of more effective interference blockers, thereby driving market growth. For instance, in July 2023, the life science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, launched two new immunoassay interference blockers, K-Block, and Mouse-Free IgG. These innovative blockers are 100% animal-free and have equivalent or superior performance compared to traditional animal-derived blockers. Thus, availability of such products in the market will spur the industry growth.

Immunoassay interference blockers are substances or reagents used to minimize or eliminate non-specific binding, cross-reactivity, and interference in immunoassay-based assays. Immunoassays rely on the specific interaction between an antibody and its target antigen to detect and quantify analytes of interest in biological samples. Also, immunoassay interference can cause false positive and false negative test results, leading to misinterpretation and improper patient diagnosis. The most common causes of interference are due to human anti-mouse antibodies (HAMA), rheumatoid factor (rf), and heterophilic antibodies (ha).
 

Immunoassay Interference Blocker Market Trends

• The rise in the prevalence of chronic diseases has sparked a corresponding increase in the demand for immunoassay interference blockers. Chronic diseases such as cancer, cardiovascular disorders, diabetes, and autoimmune conditions pose significant challenges in diagnosis and management. Therefore, immunoassays are pivotal in detecting biomarkers associated with these diseases, aiding in early diagnosis, prognosis, and treatment monitoring.
   
• For instance, as per the report published by World Health Organization in September 2023, noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Each year, 17 million people die from NCD before age 70. Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers, chronic respiratory diseases, and diabetes. Thus, the escalating prevalence of chronic diseases underscores the importance of advanced immunoassay interference blockers in improving patient outcomes and driving innovation in diagnostic technologies that will boost the growth of the market.
   

Immunoassay interference blocker Market Analysis

Based on the product, the market is classified into antibody interference blocker, detection interference blocker, and surface interference. The antibody interference blocker segment dominated the market with revenue of USD 155.6 million in 2023.
 

• Antibody interference blockers provide better accuracy of the assay and are utilized to reduce non-specific interaction and other interference.
   
• Moreover, the growing biopharmaceutical industry, particularly in the development of biologics and monoclonal antibodies, drives the demand for immunoassays in various stages of drug discovery, development, and production. Therefore, antibody interference blockers are essential for ensuring the accuracy of immunoassay-based assays in this sector, thereby fueling market growth.
   

Based on the application, the global immunoassay interference blocker market is classified into sandwich immunoassay, competitive ELISA, and other applications. The sandwich immunoassay segment dominated the market with market share of 44.6% in 2023.
 

• Sandwich immunoassays play a crucial role in detecting disease biomarkers for early diagnosis, prognosis, and treatment monitoring. The increasing prevalence of chronic diseases drives the demand for sandwich immunoassays and, consequently, the demand for interference blockers to ensure assay accuracy.
   
• Moreover, sandwich immunoassays are commonly used in point-of-care testing (POCT) devices for the detection of biomarkers related to infectious diseases, cardiac markers, and pregnancy hormones, among others. Thus, interference blockers compatible with POCT platforms are in demand to improve the accuracy and reliability of these rapid diagnostic tests, thereby augmenting the segmental growth.
   

Based on the technology, the global immunoassay interference blocker market is classified into ELISA, chemiluminescence immunoassays, fluorescence immunoassays, latex agglutination, and other technologies. The ELISA is expected to reach USD 194.9 million by end of 2032.
 

• The broad applicability of ELISA technology across diverse fields drives demand for interference blockers that can enhance the accuracy and reliability of ELISA-based assays.
   
• Also, interference blockers play a crucial role in maintaining the high specificity of ELISA assays by minimizing interference from endogenous substances, contaminants, and nonspecific binding events, thereby ensuring the accuracy of results that will in turn drive the product demand.
   

Based on end-use, the immunoassay interference blocker market is classified into biotechnology companies, contract research organization, academic & research institutes, and other end-users. Biotechnology companies’ segment is expected to exhibit 6.6% CAGR between 2024 – 2032.
 

• Biotechnology companies often form strategic collaborations and partnerships with academic institutions, research organizations, and diagnostic companies to leverage complementary expertise, resources, and technologies. These collaborations facilitate the development and commercialization of innovative interference blockers and immunoassay platforms, driving market growth and expansion opportunities for biotechnology companies.
   
• Moreover, the globalization of biotechnology markets creates new opportunities for companies to introduce interference blockers and immunoassay technologies to underserved regions, driving market growth and revenue expansion.
   

In 2023, North America secured a substantial market share of 43.2% in the global immunoassay interference blocker market and is expected to dominate throughout the forecast period.
 

• North America boasts a well-established healthcare infrastructure with sophisticated laboratory facilities and a high adoption rate of advanced diagnostic technologies. Therefore, the availability of advanced laboratory equipment and skilled healthcare professionals creates a conducive environment for the adoption of immunoassay interference blockers to improve the accuracy and reliability of diagnostic tests.
   
• Moreover, availability of advanced robust biotechnology and pharmaceutical industry, comprising numerous companies engaged in research, development, and manufacturing of biologics, therapeutics, and diagnostic products in North America, drives the demand for immunoassay interference blockers. These blockers are essential to support drug discovery, development, and clinical trials, as well as to ensure the quality and reliability of diagnostic assays.
   

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.
 

• The increase in emphasis on precision medicine and personalized healthcare approaches is the major factor that increases the demand for immunoassay interference blocker. Hence, immunoassay interference blockers play a critical role in ensuring the accuracy and reliability of biomarker measurements, supporting the advancement of precision medicine initiatives in Germany.
   

The India immunoassay interference blocker market is expected to grow with a significant CAGR during the forecast period.
 

• India faces a significant burden of infectious diseases such as tuberculosis, malaria, dengue, and HIV/AIDS. Therefore, immunoassays are essential for the detection and monitoring of infectious disease biomarkers. Thus. the demand for interference blockers is driven by the need to enhance the accuracy and reliability of immunoassays used for infectious disease diagnosis and surveillance in India.
   

• Further, the healthcare infrastructure is expanding, with investments in healthcare facilities, laboratory equipment, and skilled healthcare professionals. As access to healthcare services improves, there is a corresponding increase in the adoption of advanced diagnostic technologies, including immunoassays and interference blockers, to improve patient care and outcomes. Such aforementioned factors is expected to spur the country level market growth.
   

Immunoassay Interference Blocker Market Share

The competitive landscape of the immunoassay interference blocker industry is characterized by the presence of established biopharmaceutical companies that involved in the manufacturing of technologically advanced immunoassay interference blocker vying for market share. Key players are engaging in strategic initiatives such as product launch, collaboration, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for immunoassay interference blocker.
 

Immunoassay Interference Blocker Market Companies

Prominent players operating in the immunoassay interference blocker industry are as mentioned below:

• Meridian Bioscience
• F. Hoffmann La Roche Ltd.
• Candor Bioscience GmbH
• Nordic Biosite
• Bio-Rad Laboratories Inc.
• Aviva Biosystem Biology Corporation
• Scantibodies Laboratory Inc.
• Rockland Immunochemicals Inc.
• Abcam PLC
• Thermo Fisher Scientific Inc.
• Surmodic IVD Inc.
• Electron Microscopy Science
• Merck KGaA
• Jackson ImmunoResearch Inc.
   

Immunoassay Interference Blocker Industry News:

• In February 2021, Abingdon Health had signed a collaboration and co-marketing agreement with Abcam plc, to enable them to identify and maximize opportunities for the provision of each party’s respective products and services, including the wider Abcam reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services. This strategy enabled company to enhance their business relation and expand their product offerings.
   

The immunoassay interference blocker market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Antibody interference blocker
  • Human serum derived
  • Animal serum derived
  • Human immunoglobulin blocker
  • Animal polyclonal antibody
  • Heterophilic blocking agent
• Detection interference blocker
  • Enzyme blocker
  • Beta-galactosidase blocker
  • Alkaline phosphate blocker
• Surface interference
  • Poly BSA blocker
  • Bovine serum albumin blocker
  • BSA fraction V blocker
  • Blocking buffer

Market, By Application

• Sandwich immunoassay
• Competitive ELISA
• Other applications

Market, By Technology

• ELISA
• Chemiluminescence immunoassays
• Fluorescence immunoassays
• Latex agglutination
• Other technologies

Market, By End-use

• Biotechnology companies
• Contract research organizations
• Academic & research institutes
• Other end-users  

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa